Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial

This publication has 29 references indexed in Scilit:

• Antiviral prophylaxis in haematological patients: Systematic review and meta-analysis
  European Journal Of Cancer, 2009
• How we treat cytomegalovirus in hematopoietic cell transplant recipients
  Blood, 2009
• Effect of Conditioning Regimen Intensity on CMV Infection in Allogeneic Hematopoietic Cell Transplantation
  Transplantation and Cellular Therapy, 2009
• Surrogate and Mediating Endpoints: Current Status and Future Directions
  JNCI Journal of the National Cancer Institute, 2009
• Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study
  Blood, 2008
• Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis
  Blood, 2007
• Cytomegalovirus prophylaxis and treatment after hematopoietic stem cell transplantation in Canada: a description of current practices and comparison with Centers for Disease Control/Infectious Diseases Society of America/American Society for Blood and Marrow Transplantation guideline recommendations
  Transplantation and Cellular Therapy, 2004
• Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation
  Bone Marrow Transplantation, 2002
• Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole l -Riboside with a Unique Mode of Action
  Antimicrobial Agents and Chemotherapy, 2002
• PLASMA POLYMERASE CHAIN REACTION FOR CYTOMEGALOVIRUS DNA AFTER ALLOGENEIC MARROW TRANSPLANTATION
  Transplantation, 1997